Eli Lilly: GLP-1 Market Leader Grows by 48% in Record Quarter - Stock Near All-Time High!
Reading Time: 3 minutes
The second quarter impresses with a revenue growth of 48%. Mounjaro and Zepbound set a revenue record with $14.9 billion. The oral weight loss pill Foundayo and the triple agonist Retatrutide offer additional growth potential. High costs for research and acquisitions weigh on performance. However, the revenue forecast for fiscal year 2026 has been raised to $85-87 billion. Eli Lilly (LLY) is experiencing strong demand for GLP-1 formulations Mounjaro for type 2 diabetes and Zepbound for obesity. Eli Lilly claims a global market...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
